Cellectar Biosciences to Present at Multiple Medical Meetings and Industry Conferences in September.

Cellectar Biosciences will participate in multiple medical meetings and industry conferences in September. CEO Jarrod Longcor will present at the ADC and Novel Conjugates Partnering and Investment Summit, BioProcess International, Targeted Radiopharmaceuticals (TRP) Supply Chain and Manufacturing, American Association for Cancer Research Special Conference in Cancer Research: Discovery and Innovation in Pediatric Cancer, and American Association for Cancer Research Special Conference in Cancer Research: Advances in Pancreatic Cancer Research. The company is focused on developing drugs for cancer treatment using its proprietary Phospholipid Drug Conjugate™ platform.

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for cancer treatment, has announced that its Chief Operating Officer, Jarrod Longcor, will participate in several medical meetings and industry conferences in September. These events include the ADC and Novel Conjugates Partnering and Investment Summit, BioProcess International, Targeted Radiopharmaceuticals (TRP) Supply Chain and Manufacturing, and the American Association for Cancer Research Special Conference in Cancer Research, with two specific focuses: Discovery and Innovation in Pediatric Cancer and Advances in Pancreatic Cancer Research [1].

Cellectar Biosciences is committed to leveraging its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments. The company's product pipeline includes lead assets such as iopofosine I 131, CLR 121225, and CLR 121125, which are designed to target various cancer types, including multiple myeloma, CNS lymphoma, and pancreatic cancer [1].

The company has been actively engaged in clinical trials, with iopofosine I 131 studied in Phase 2b trials for relapsed or refractory multiple myeloma and CNS lymphoma, and the CLOVER-2 Phase 1b study targeting pediatric patients with high-grade gliomas. Cellectar Biosciences has received multiple designations from the FDA, including Orphan Drug, Rare Pediatric Drug, and Fast Track Designations for various cancer indications [1].

This increased visibility at key industry events underscores Cellectar Biosciences' dedication to advancing its innovative cancer treatment solutions and engaging with stakeholders in the medical and biopharmaceutical communities.

References:
[1] https://www.stocktitan.net/news/CLRB/cellectar-biosciences-to-participate-in-multiple-upcoming-medical-579cipk88zmt.html
[2] https://finance.yahoo.com/news/cellectar-biosciences-participate-multiple-upcoming-124500374.html